As DDS drugs with various drug delivery functions are often prescribed under in conbination with a widerange of concurrent drug therapies, drug information closely related to its clinical usage is required to guarantee the appropriate multiple pharmaceutical functions of DDS drugs: We surveyed the actual concurrent therapy of lipo-PGE1 (Palux® inj. and Liple®), a targeting-type DDS, with various aqueous infusions at both Okayama University Hospital and Fukui Medical School Hospital. The term of the survey, which was done by evaluating the prescription records, and the total number of prescriptions were 14 months and 1, 005 prescriptions, respectively. Lipo-PGE1 was scarcely administered without any concurrently prescribed infusions. Although lipo-PGE1 was mostly diluted with Glucose Injection or Isotonic Sodium Chloride Solution, some electrolyte infusions were also concurrently prescribed with Lipo-PGE1 in some cases. The magnification of the dilution and the administration route seemed to be related each other. The data revealed in this report ave considered to be useful for a clinical usage-based assessment system to obtain further information guaranteeing the drug delivery function of Lipo-PGE1 from both a pharmaceutical and pharmacodynamic viewpoint one word.
